Literature DB >> 6356357

Translocations among antibody genes in human cancer.

P Leder, J Battey, G Lenoir, C Moulding, W Murphy, H Potter, T Stewart, R Taub.   

Abstract

The characteristic chromosomal translocations that occur in certain human malignancies offer opportunities to understand how two gene systems can affect one another when they are accidentally juxtaposed. In the case of Burkitt lymphoma, such a translocation joins the cellular oncogene, c-myc, to a region encoding one of the immunoglobulin genes. In at least one example, the coding sequence of the rearranged c-myc gene is identical to that of the normal gene, implying that the gene must be quantitatively, rather than qualitatively, altered in its expression if it is to play a role in transformation. One might expect to find the rearranged c-myc gene in a configuration that would allow it to take advantage of one of the known immunoglobulin promoters or enhancer elements. However, the rearranged c-myc gene is often placed so that it can utilize neither of these structures. Since the level of c-myc messenger RNA is often elevated in Burkitt cells, the translocation may lead to a deregulation of the c-myc gene. Further, since the normal allele in a Burkitt cell is often transcriptionally silent in the presence of a rearranged allele, a model for c-myc regulation is suggested that involves a trans-acting negative control element that might use as its target a highly conserved portion of the c-myc gene encoding two discrete transcriptional promoters.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6356357     DOI: 10.1126/science.6356357

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  200 in total

1.  Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene.

Authors:  B C Lewis; H Shim; Q Li; C S Wu; L A Lee; A Maity; C V Dang
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  DNA inversions between short inverted repeats in Escherichia coli.

Authors:  M A Schofield; R Agbunag; J H Miller
Journal:  Genetics       Date:  1992-10       Impact factor: 4.562

3.  Streamlined approach to creating yeast artificial chromosome libraries from specialized cell sources.

Authors:  J M Feingold; S D Ogden; C T Denny
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

4.  Homologous plasmid recombination is elevated in immortally transformed cells.

Authors:  G K Finn; B W Kurz; R Z Cheng; R J Shmookler Reis
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

5.  Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model.

Authors:  E V Schmidt; P K Pattengale; L Weir; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations.

Authors:  Davide F Robbiani; Anne Bothmer; Elsa Callen; Bernardo Reina-San-Martin; Yair Dorsett; Simone Difilippantonio; Daniel J Bolland; Hua Tang Chen; Anne E Corcoran; André Nussenzweig; Michel C Nussenzweig
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

Review 7.  Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants.

Authors:  L Larizza; V Schirrmacher
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

8.  Accurate and efficient transcription of human c-myc genes injected into Xenopus laevis oocytes.

Authors:  K Nishikura; S Goldflam; G A Vuocolo
Journal:  Mol Cell Biol       Date:  1985-06       Impact factor: 4.272

Review 9.  An approach to oncological genetics.

Authors:  P Tautu; G Wagner
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

10.  Human proto-oncogene N-myc encodes nuclear proteins that bind DNA.

Authors:  G Ramsay; L Stanton; M Schwab; J M Bishop
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.